SHYNDEC(SH:600420)2024-04-29 09:05Financial Performance - The company's operating revenue for Q1 2024 was CNY 3,123,407,807.27, representing a decrease of 8.60% compared to the same period last year[11]. - Net profit attributable to shareholders of the listed company reached CNY 331,257,150.18, an increase of 84.83% year-on-year[11]. - The net profit after deducting non-recurring gains and losses was CNY 325,926,581.84, reflecting a growth of 91.04% compared to the previous year[11]. - Basic earnings per share were CNY 0.2470, up by 61.54% compared to the same period last year[11]. - Diluted earnings per share also stood at CNY 0.2470, an increase of 79.51% year-on-year[11]. - The company achieved a profit margin of approximately 13.6% in Q1 2024, up from 8.0% in Q1 2023, reflecting improved operational efficiency[40]. Cash Flow - The net cash flow from operating activities was CNY 711,404,907.55, showing a significant increase of 163.91% year-on-year[11]. - The company reported a significant increase in cash flow due to improved cash collection rates, contributing to the overall growth in net profit indicators[11]. - Cash received from operating activities totaled ¥3,139,913,318.15 in Q1 2024, an increase of 17.6% from ¥2,666,870,661.29 in Q1 2023[44]. - Cash flow from operating activities showed a net outflow of CNY 118.53 million in Q1 2024, compared to a net outflow of CNY 8.57 million in Q1 2023[61]. - The cash flow from operating activities increased to ¥2,927,957,863.30 in Q1 2024, compared to ¥2,458,359,184.90 in Q1 2023, representing a growth of 19.1%[42]. Assets and Liabilities - Total assets as of March 31, 2024, were CNY 19,851,985,613.99, up 2.58% from the end of the previous year[13]. - Current liabilities rose to ¥4,889,335,372.36, up from ¥3,779,675,395.01, indicating an increase of about 29.4%[20]. - Total liabilities slightly increased to ¥5,087,913,657.80 from ¥5,014,068,776.55, reflecting a growth of approximately 1.5%[20]. - Total liabilities decreased to CNY 1.66 billion as of March 31, 2024, from CNY 3.01 billion as of December 31, 2023, a reduction of approximately 44.7%[57]. - The company's total equity increased to ¥14,764,071,956.19 as of March 31, 2024, compared to ¥14,338,213,684.05 at the end of 2023, marking a growth of 3.0%[38]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 35,972[30]. - The largest shareholder, Shanghai Pharmaceutical Industry Research Institute Co., Ltd., holds 17.86% of the shares[30]. Expenses - Total operating costs decreased to ¥2,626,556,816.56 in Q1 2024 from ¥3,077,218,082.04 in Q1 2023, reflecting a reduction of 14.6%[40]. - Research and development expenses rose to ¥121,609,766.63 in Q1 2024, compared to ¥110,631,302.54 in Q1 2023, indicating an increase of 9.9%[40]. - The company reported a significant reduction in sales expenses, which fell to ¥453,603,798.38 in Q1 2024 from ¥715,994,328.19 in Q1 2023, a decrease of 36.6%[40]. Inventory and Other Assets - The company's inventory increased to CNY 130.10 million from CNY 123.24 million, reflecting a rise of about 5.0%[56]. - Cash and cash equivalents amounted to ¥6,414,879,654.28, compared to ¥5,972,611,230.69 in the previous period, reflecting a growth of approximately 7.4%[34]. - Cash and cash equivalents at the end of Q1 2024 were CNY 2.87 billion, up from CNY 2.38 billion at the end of Q1 2023, an increase of about 21.5%[62].